Monoclonal Antibodies Market Size, Share, Growth Analysis, By Source type(Murine, Chimeric, Humanized, Human), By Production Type(In Vivo, In Vitro), By Application(Oncology, Autoimmune Diseases, Infectious Diseases, Neurological Diseases), By End-use(Hospitals, Specialty Centers, Others), By Region - Industry Forecast 2024-2031

Global Monoclonal Antibodies Market size was valued at USD 211 billion in 2022 and is poised to grow from USD 235.27 billion in 2023 to USD 562.03 billion by 2031, growing at a CAGR of 11.5% during the forecast period (2024-2031).

An increase in requirement for biologics, especially mAbs, is mainly fuelled by the ever-rising prevalence of chronic diseases such as cancer, cardiovascular disease, and autoimmune diseases. Such trends are predicted to mark the dominating presence of the mAbs market. Increasing levels of awareness among patients and doctors are being created as monoclonal antibodies for targeted treatment start to work for significant numbers of health-care professionals. Since monoclonal antibodies can selectively interact with and neutralize disease-causing chemicals, it has emerged as one of the direct medical needs in the fight against a broad spectrum of diseases. 

Global-leading companies in the industry have made great efforts in developing and commercializing mAb drugs. For instance, T-Cure Bioscience, Inc. collaborated with Atlas Antibodies AB in October 2021 to improve CT83 mAbs production and supply in cancer treatment applications. Of a similar sort, Ono Pharmaceutical Co., Ltd. and Neurimmune AG agreed in January 2022 to collaborate for developing mAb drugs targeting novel therapeutic targets of neurodegenerative diseases. These new and innovative partnerships are most expected to unlock opportunities for growth of the mAbs sector with regard to improved treatment options and betterment of patient care for most chronic conditions.